OPPORTUNITIES FOR OPTIMIZATION OF DRUG THERAPY BY ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AND ATRIAL SEPTOSTOMY
https://doi.org/10.38109/2225-1685-2018-4-88-97
Abstract
The initiation of PAH-specific therapy in this case of IPAH was preceded by atrial septostomy. The chosen treatment plan put the patient at an unacceptable risk and did not contribute to the improvement of her clinical condition. The clinical case described in the paper demonstrates the importance of a reasonable approach to the implementation of palliative surgical interventions in patients with pulmonary hypertension in accordance with modern guidelines, as well as the possibility of optimizing drug therapy with endothelin receptor antagonists.
About the Authors
V. V. Gramovich
National Medical Research Center of Cardiology of the Ministry of Health of the Russia
Russian Federation
Russian Federation
PhD, Senior Researcher of the Department of Pulmonary Hypertension and Heart Disease
tel. +7 (495) 414-68-61
121552, Moscow, 3-ya Cherepkovskaya St., 15 a
A. M. Aleevskaya
National Medical Research Center of Cardiology of the Ministry of Health of the Russia
Russian Federation
Russian Federation
Clinical intern of the Department of Pulmonary Hypertension and Heart Disease
tel. +7 (495) 414-68-02
121552, Moscow, 3-ya Cherepkovskaya St., 15 a
T. V. Martynyuk
National Medical Research Center of Cardiology of the Ministry of Health of the Russia
Russian Federation
Russian Federation
MD, Head of the Department of Pulmonary Hypertension and Heart Disease
tel. +7 (495) 414-64-50
121552, Moscow, 3-ya Cherepkovskaya St., 15 a
References
1. Martynyuk T.V. Pulmonary hypertension: diagnosis and treatment/ T.V. Martynyuk. – Moscow: LLS “Medical
2. information agency “, 2018. p. 304 [in Russian].
3. Galiè N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016 Jan 1;37(1):67-119.
4. Humbert M, Sitbon O, ChaouatA et al. Survival in patients with idiopathic, familial and anorexigen-assotiated pulmonary arterial hypertension in the management era. Am J RespirCrit Care Med 2010; 181: А4812
5. Chazova I.Ye., Martynyuk T.V. Pulmonary hypertension. М.: Practice, 2015 [in Russian].
6. D’Alonzo G.E., Barst R.J., Ayres S.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern Med. 1991;115; 343-349.
7. Chazova I.Ye., Avdeev S.N., Tsareva N.A., Volkov A.V., Martynyuk T.V., Nakonechnikov S.N. Clinical guidelines for the diagnosis and treatment of pulmonary hypertension. Therapeutic archive. 2014; 9: 4-23 [in Russian].
8. Sandoval J., Torbick A. In: Voelkel N.F., Schranz D. Right Ventricle in Health and Disease. NY: Humans Press, Springer Science; 2015: 419-437.
9. Tracleer E.U. Summary of Product Characteristics (SPC). Actelion Pharmaceuticals Ltd. 14.07.2017; Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000401/WC500041597.pdf
10. Martynyuk T.V., Nakonechnikov S.N., Chazova I.Ye. Optimization of specific therapy for pulmonary arterial hypertension: the possibility of using endothelin receptor antagonists. Eurasian Heart Journal. 2017 May 25;2:20-27 [in Russian].
Review
For citations:
Gramovich V.V., Aleevskaya A.M., Martynyuk T.V. OPPORTUNITIES FOR OPTIMIZATION OF DRUG THERAPY BY ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AND ATRIAL SEPTOSTOMY. Eurasian heart journal. 2018;(4):88-97. https://doi.org/10.38109/2225-1685-2018-4-88-97
Views:
299
Email this article 
